As of November 6, 2026, Ironwood Pharmaceuticals Inc. is a publicly traded company (Nasdaq: IRWD). The largest holder reporting an active stake on Schedule 13D is Sarissa Capital Management LP, at 5.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Armistice Capital (8.43%), BlackRock (8.1%), State Street (5.4%) (Schedule 13D/A, March 19, 2026).
Is this your company?
About to sign with, pay or invest in Ironwood Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Ironwood Pharmaceuticals Inc. a real, registered company?
- Ironwood Pharmaceuticals Inc files with the SEC under CIK 1446847 (its SEC filings).
- Its shares are listed under the ticker IRWD on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under IRONWOOD PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Tammi Gaskins, Chief Executive Officer (Form 8-K filed 2026-10-16). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Ironwood Pharmaceuticals Inc.'s owners and officers?
Ironwood Pharmaceuticals Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-28 | Bank Of America Corp /De/ | 3.2% |
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 8.43% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.4% |
| Schedule 13G/A, 2026-07-28 | Blackrock, Inc. | 8.1% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 9.22% |
| Schedule 13G/A, 2026-05-14 | Renaissance Technologies LLC | 4.9% |
| Schedule 13G/A, 2026-04-27 | Bank Of America Corp /De/ | 6.1% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13D/A, 2026-03-19 | Sarissa Capital Management LP | 5.8% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 9.85% |
| Schedule 13G, 2025-11-14 | Bank Of America Corp /De/ | 7.4% |
| Schedule 13G/A, 2025-11-12 | Barclays PLC | 1.95% |
Questions about who owns Ironwood Pharmaceuticals Inc.
Who owns Ironwood Pharmaceuticals Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Ironwood Pharmaceuticals Inc.: Armistice Capital, LLC (8.43%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (8.1%, Schedule 13G/A, filed 2026-07-28), Sarissa Capital Management LP (5.8%, Schedule 13D/A, filed 2026-03-19) and State Street Corporation (5.4%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Ironwood Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Ironwood Pharmaceuticals Inc. on this page are Armistice Capital, LLC (8.43%), Blackrock, Inc. (8.1%) and Sarissa Capital Management LP (5.8%).
When did Armistice Capital, LLC buy into Ironwood Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.85%; its latest, Schedule 13G/A filed 2026-08-14, reports 8.43%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Ironwood Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ironwood Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ironwood Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-16 | Tammi Gaskins | Chief Executive Officer | appointed | 2027-01-01 |
| Form 8-K, 2026-10-16 | Tammi Gaskins | Director | appointed | |
| Form 8-K, 2026-10-16 | Thomas McCourt | Chief Executive Officer | departed | 2026-12-31 |
| Form 8-K, 2026-05-13 | Gregory Martini | Chief Financial Officer | departed | 2026-05-15 |
Which insiders own Ironwood Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Sarissa Capital Management LP, a 10% owner: 16,171,293 shares (9.8% of shares outstanding), 251,858 held directly and 15,919,435 indirectly, on a joint filing (Form 4, 2025-12-17).
- , the chief executive and a director: 1,898,838 shares (1.1% of shares outstanding) (Form 4, 2026-03-12).
- , a director: 676,900 shares (0.41% of shares outstanding) (Form 4, 2026-06-17).
- , the senior vice president and chief marketing officer: 658,037 shares (0.40% of shares outstanding) (Form 4, 2026-03-12).
- , the chief legal officer: 500,498 shares (0.30% of shares outstanding) (Form 4, 2026-03-12).
Shares outstanding: 165,550,760 as of 2026-10-31, from the company's latest SEC cover page.
How much has Ironwood Pharmaceuticals Inc. raised?
No fundraising or offering filing from Ironwood Pharmaceuticals Inc. is on file with us.
Keep reading
More on Ironwood Pharmaceuticals Inc. and the records around it.
Ironwood Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jun 2026
Companies that share a holder
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Bolt Biotherapeutics, Inc. (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ironwood-pharmaceuticals